Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)

NCT02460198 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab

Sponsor

Merck Sharp & Dohme LLC